Astellas puts the cork back in $350M Xork deal after Cartesian-Selecta merger

Astellas is putting the kibosh on a licensing deal with Cartesian Therapeutics, deciding it’s no longer interested in using the latter’s Xork asset to help treat Pompe disease.

The decision disclosed Thursday swiftly ends a collaboration announced just over a year ago. The January 2023 deal was technically with Selecta Biosciences, which has since merged with Cartesian.